Background: Previous work reported the benefits of extracts of 2 Cameroonian spices -Irvingia gabonensis and Dichrostachys glomerata-on obese people with metabolic syndrome. Considering the physio-metabolic changes that accompany obesity, the present study investigates the effects of these extracts on healthy overweight participants over an 8-week test period.
INTRODUCTION
Obesity is a multifaceted disease which generally leads to several complications and increased morbidity and mortality related to coronary heart diseases, diabetes type 2, metabolic syndrome, stroke and cancers [1, 2] . To become obese, healthy individuals generally experience progression from normal weight, to being overweight (considered generally as being healthy), and finally to obese (considered as being an unhealthy or diseased state). Treatment or management of obesity is difficult, due the complexity of associated complications. Therefore, attempts to prevent progression in body weight and fat accumulation, from an overweight/pre-obese condition to obesity, can lower worldwide mortality rates related to obesity. This study investigates the effects of the extracts of Irvingia gabonensis (IGOB131) and Dichrostachys glomerata (Dyglomera TM ) on healthy overweight participants over an 8-week test period.
PARTICIPANTS AND METHODS
A total of 48 overweight participants aged between 23 and 55 years were selected from a group of 220 overweight and obese persons responding to a radio advertisement in Yaoundé, Cameroon. After physical examination and laboratory screening tests, diabetics, pregnant and lactating women were excluded. All participants were judged as healthy (normal range of temperature, no clinical consultation within the previous 2 weeks) by the resident physician, and were not on any weight reducing protocol. The purpose, nature and potential risks of the study were explained to all patients and a written informed consent was obtained before their participation. The local research ethics committee approved the experimental protocol.
Study design: Participants were given one of three different types of capsules containing either 300mg of Irvingia gabonensis extract (IGOB131, with ≥7% albumin and ≥1% ellagic acid), 300 mg of hydroethanolic (90:10, water :ethanol) extract of Dichrostachys glomerata (Dyglomera™) or oat bran (placebo). The capsules were taken one-half hour before the main meal with a glass of warm water. Capsules were identical in shape, colour, and appearance, with neither participant nor researchers knowing what capsule they received. During the 8 week experimental period, participants were examined weekly, with their body weight, body fat, waist and hip circumferences recorded each time. Subjective findings, such as increased or decreased appetite, feeling of lightness and gastrointestinal pains, were individually noted. The participants were also interviewed about their physical activity and food intake during the trial, and were instructed not to modify these habits.
Anthropometric measurements:
The heights of participants were measured during the first visit and their weights at each subsequent visit. BMI was also calculated, and served as a basis of inclusion or exclusion in the study. The percent body fat was measured with a Tanita™ BC-418
Body Composition Analyzer/Scale, while waist and hip circumferences were measured with a soft non-stretchable plastic tape. In an effort to ensure intra-individual consistency, the participants were measured at approximately the same time of the day for each visit.
Laboratory methods: Blood samples were collected after a 12h overnight fast into heparinized tubes at the beginning of the study, after four weeks, and at the end (8 weeks) of treatment. 
RESULTS
There were 3 dropouts, two of whom relocated to a different town, and the third, who gave no specific reason. No adverse side effects were reported.
Effect of IGOB131 and Dyglomera™ on Body weight
Overweight participants who received either IGOB131 or Dyglomera (300mg daily) for 8 weeks had significantly (p<0.05) greater reduction in body weight compared to those on placebo (Table  1a ). This reduction in body weight corresponded to a 9-10% reduction in BMI (Table 1b) . 
Values are means ± sem
There was a slight but insignificant decrease in weight and BMI for participants taking placebo over the 8 -week test period. 
Body weight, BMI, % body fat, and waist-to-hip circumferences were slightly (1.3%, 0.8 cm, 2.0 cm respectively) reduced in the placebo group over the 8 week trial period. However, IGOB131, as well as Dyglomera™, brought about a more significant reduction in these parameters (Tables 1c, 1d and 1e). Values are means ± sem.
Effect of IGOB131 and Dyglomera™ on Blood lipids
Eight-week use of IGOB131 by overweight participants reduced plasma total cholesterol by 10.5%, LDL-cholesterol by 24.7%, and triacylglycerol by 12.2%. This treatment also increased the concentration of HDL-cholesterol by 12.1% (Tables 2, 3, 4) . A similar change in these parameters was observed in the Dyglomera™ group; 8.45% for total cholesterol, 17.27% for LDL-cholesterol and 14.30% for triglycerides. There was also a 13.36% increase in HDLcholesterol. Values are means ± sem. Values are means ± sem.
Over the 8-week test period, the circulating levels of HDL-cholesterol were also significantly increased (p<0.05) by Dyglomera™, as well as IGOB131 (Table 5 ). 
DISCUSSION
Results demonstrated that the extracts at a dose of 300 mg per day, were effective in significantly reducing weight, BMI, body fat, waist circumference, and hip circumference. IGOB131 and Dyglomera TM also positively modified lipid parameters in healthy overweight participants. These findings are superior to the majority of other randomized double-blind placebo-controlled clinical trials evaluating medicinal plant extracts, herbs and spices. For example, recently, an 8-week study carried out on 78 overweight subjects with Cuminum cyminum L. and Orlistat 120, showed significant decreases in weight (-1.1 ± 1.2 and -0.9 ± 1.5 vs. 0.2 ± 1.5 kg, respectively, p = 0.002) and BMI (-0.4 ± 0.5 and -0.4 ± 0.6 vs. 0.1 ± 0.6 kg/m 2 , respectively, p = 0.003), in addition to beneficial effects on insulin metabolism compared with placebo [3] . Comparing those results to our study, the reduction in weight observed is nine times higher with IGOB131 and eight times higher with Dyglomera TM than C. cyminum. IGOB131 and Dyglomera TM reduced BMI 25 times and 22 times respectively, more effective than C. cyminum in overweight subjects and maintaining participants within a healthy BMI bracket. The activity of plant extracts can be explained through the action some of their components have on body-fat metabolism and oxidation or increasing metabolic rate [1] . This has been demonstrated in trials with epigallocatechin-3-gallate of green tea, virgin olive oil, and Lycium barbarum causing higher fat oxidation in human. The compounds may act by activating lipid metabolism, acceleration of oxidation, suppression of fatty acid synthesis and PPARc agonistic activity in overweight individuals, as well as in obese patients.
IGOB131 and Dyglomera TM have previously proven their activities with overweight and/or obese volunteers (defined as BMI > 25 kg/m 2 ). In a previous study [4] on 102 healthy overweight and obese participants who were administered a dose of 150 mg twice daily before meals, there were significant improvements in body weight, body fat, and waist circumference, as well as plasma total cholesterol, LDL cholesterol, blood glucose, C-reactive protein, adiponectin and leptin levels compared to a placebo group. IGOB131 was also very active in overweight participants in this study. In both obese and overweight groups, IGOB131 activity was attributed to the ability of the extracts to favorably impact adipogenesis through a variety of critical metabolic pathways, including PPAR gamma, leptin, adiponectin, and glycerol-3 phosphate dehydrogenase [5] . Furthermore, compared to the placebo group, the obese group treated with Dyglomera™ demonstrated a significant average weight reduction of 11.15 kg (-11.33% of total body weight) (p < 0.001) after 8 weeks of treatment (Table 1a ). This reduction in weight was accompanied by a loss of visceral fat, as measured by waist circumference and lipid profiles [6] . The same trend was observed with overweight participants (Tables 2, 3 , 4, 5). The present study clearly demonstrates that administration of IGOB131 and Dyglomera™ can be used to prevent and manage weight increase, specifically targeting to limit the progression to obesity and the myriad of its complications. The antioxidant properties of both extracts have been intensively documented, and are suggested to be involved with curative activity [7] . However, there are only a few and controversial studies on oxidative stress in overweight subjects compared to obesity studies [8] . For example, one study demonstrated that oxidative stress increases with increasing BMI and age, as a sequel to an impaired antioxidant status, in addition to an increase of peroxides and uric acid and a disadvantaged lipid profile in overweight subjects. In contrast, another study [9] demonstrated that oxidative stress is not involved in the overweight status. However, it is established that lipid peroxidation is associated with several indices of adiposity and a low systemic antioxidant defense (i.e. antioxidant enzymes, tissue dietary antioxidants, glutathione [10] , and leading to oxidative stress. In fact, in stress conditions ROS levels increase; because of their high reactivity, they are involved in cell damage, necrosis, and apoptosis, via oxidation of lipids, proteins, and DNA, in addition to provoking an endothelial dysfunction, infiltration, and activation of inflammatory cells [11] . The anti-oxidant property of the IGOB131 used in this study can be attributed to the presence of ellagic acid (EA). This polyphenolic compound has been shown to be antiproliferative and anti-inflammatory [12, 13] . Additionally, its efficacy in the management of obesity and metabolic syndrome has previously been reported [6] .
The present study has also proven the capacity of these extracts to reduce body fat (Table  1c) , waist and hip circumferences (Tables 1d and 1e respectively), total cholesterol (Table 2) , triglyceride (Table 3) , and LDL cholesterol levels (Table 4) in overweight participants. The observed reduction may be due to the presence of EA in IGOB131. In fact, lipid accumulation both in adipose tissue and liver are associated with increasing weight; progression to an overweight condition [13] and changes in weight are partially due to the metabolic reactions and differentiation occurring in the adipose tissue. This can explain hypertrophy and hyperplastic expansion of adipocytes associated with being overweight and obese. Furthermore, EA has a lipid-lowering dietary compound; its inhibitory effects on adipogenesis seem to be associated, at least partly, with epigenetic modification. EA decreases hepatic lipid accumulation by targeting multiple mechanisms including FFA synthesis, TG sterification and FFA oxidation. In a recent study [12] , there was evidence that EA plays separate, differing roles in manipulating excess lipid in adipocytes and hepatocytes, resulting in a synergistic attenuation the progression from overweight state to obesity and hepatic steatosis. EA also exerted the distinctive lipid-lowering properties to decrease biosynthesis of FA in both adipocytes and hepatocytes, but augmented FA oxidation only in hepatocytes. The presence of EA in extracts has also been shown to be effective in reducing atherosclerotic lesions and increasing cholesterol efflux in macrophages. Additionally, constituents of IGOB131 and Dyglomera including EA, may act via modulation of the expression of PPAR-gamma required for maintenance of the differentiated state of adipocytes, which has been reported to be involved in lipid accumulation and decreased expression of adipocyte markers. Several other transcription factors are likely to play an important role in the molecular control of adipogenesis like C/EBPs [14] . The presence of albumin in IGOB131 extracts may also contribute to the activity observed, although the function is not well understood. Albumin has been demonstrated to bind reversibly to many endogenous molecules (e.g., fatty acids), as well as pharmacologic agents [15] . It is speculated that this combination to other constituents can play a much more important role in buffering against sudden changes in absorption, thereby providing more consistent blood levels, similar to like detemir, an insulin preparation [16] . Albumin may also contribute to prolonged duration of action caused by some of the active compounds in our extracts. Other studies proved that the addition of molecules like albumin, a soluble 66.5 kD monomeric, leads to significant improvement in the solubility of the poorly soluble compounds [17. 18] . Another explanation for the role of albumin in weight reduction and lipid profile can be described from its presence in Whey protein. In fact, the presence of albumin in whey, a dietary protein which stimulates energy expenditure, has a greater thermogenic effect in the postprandial period compared to carbohydrates and fats, and additionally decreases energy intake through mechanisms that influence appetite. Whey amino acids on insulin secretion, incretin hormones released from the gut, also seem to be involved, in particular gastric inhibitory peptide (GIP) and glucagon-like peptide 1 (GLP-1). Furthermore, the presence of albumin in our extracts could influence absorption process at the intestinal level, considering that the postprandial rate of protein synthesis also depends on the speed of protein absorption and that fast absorbing protein has an anabolic effect [19] .
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